{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:44:35Z","timestamp":1794037475193,"version":"4.8.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-026-04254-4","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:03:43Z","timestamp":1772532223000},"page":"1045-1051","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-6270","authenticated-orcid":false,"given":"Ping","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-804X","authenticated-orcid":false,"given":"Dongni","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-5574","authenticated-orcid":false,"given":"Yuming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-563X","authenticated-orcid":false,"given":"Jiaoyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1245-358X","authenticated-orcid":false,"given":"Michael","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8977-4317","authenticated-orcid":false,"given":"Zi Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-9883","authenticated-orcid":false,"given":"Yuxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6767-5027","authenticated-orcid":false,"given":"Taihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-6951","authenticated-orcid":false,"given":"Qiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"4254_CR1","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","volume":"141","author":"P Hu","year":"2020","unstructured":"Hu, P. et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease. Circulation 141, 1742\u20131759 (2020).","journal-title":"Circulation"},{"key":"4254_CR2","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490 (2013).","journal-title":"Eur. Heart J."},{"key":"4254_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"key":"4254_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154\u2013156 (2003).","journal-title":"Nat. Genet."},{"key":"4254_CR5","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","volume":"20","author":"GF Watts","year":"2023","unstructured":"Watts, G. F. et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat. Rev. Cardiol. 20, 845\u2013869 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"4254_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.atherosclerosis.2013.12.003","volume":"233","author":"SP Zhao","year":"2014","unstructured":"Zhao, S. P., Yu, B. L., Peng, D. Q. & Huo, Y. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial. Atherosclerosis 233, 707\u2013712 (2014).","journal-title":"Atherosclerosis"},{"key":"4254_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li, J. J. et al. 2023 Chinese guideline for lipid management. Front. Pharmacol. 14, 1190934 (2023).","journal-title":"Front. Pharmacol."},{"key":"4254_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.7326\/M15-0920","volume":"163","author":"M Cainzos-Achirica","year":"2015","unstructured":"Cainzos-Achirica, M., Martin, S. S., Cornell, J. E., Mulrow, C. D. & Guallar, E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann. Intern. Med. 163, 64\u201365 (2015).","journal-title":"Ann. Intern. Med."},{"key":"4254_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah, N. G., Awan, Z., Chr\u00e9tien, M. & Mbikay, M. PCSK9: a key modulator of cardiovascular health. Circ. Res. 114, 1022\u20131036 (2014).","journal-title":"Circ. Res."},{"key":"4254_CR10","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein, J. J. et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36, 2996\u20133003 (2015).","journal-title":"Eur. Heart J."},{"key":"4254_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal, F. J. et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385, 331\u2013340 (2015).","journal-title":"Lancet"},{"key":"4254_CR12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med. 382, 1520\u20131530 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4254_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2021.100180","volume":"6","author":"G Langslet","year":"2021","unstructured":"Langslet, G. et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am. J. Prev. Cardiol. 6, 100180 (2021).","journal-title":"Am. J. Prev. Cardiol."},{"key":"4254_CR14","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med. 25, 776\u2013783 (2019).","journal-title":"Nat. Med."},{"key":"4254_CR15","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu, B. et al. CRISPR\u2013Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia. Nat. Med. 28, 1573\u20131580 (2022).","journal-title":"Nat. Med."},{"key":"4254_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535\u2013541 (2020).","journal-title":"Nat. Med."},{"key":"4254_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR\u2013Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4254_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D. et al. CRISPR\u2013Cas9 in vivo gene editing for transthyretin amyloidosis. N. Engl. J. Med. 385, 493\u2013502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4254_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"4254_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"4254_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"4254_CR22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"4254_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020).","journal-title":"Nat. Biotechnol."},{"key":"4254_CR24","doi-asserted-by":"publisher","unstructured":"Liao, J. et al. Sequential amino acid mutagenesis-driven de novo evolution of adenine deaminases enables efficient in vivo base editing in primate. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.14.653640 (2025).","DOI":"10.1101\/2025.05.14.653640"},{"key":"4254_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37465-1","volume":"14","author":"LN Kasiewicz","year":"2023","unstructured":"Kasiewicz, L. N. et al. GalNAc-lipid nanoparticles enable non-LDLR dependent hepatic delivery of a CRISPR base editing therapy. Nat. Commun. 14, 2776 (2023).","journal-title":"Nat. Commun."},{"key":"4254_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","volume":"569","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433\u2013437 (2019).","journal-title":"Nature"},{"key":"4254_CR27","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel, M. et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 35, 2146\u20132157 (2014).","journal-title":"Eur. Heart J."},{"key":"4254_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11883-024-01193-8","volume":"26","author":"M Hermel","year":"2024","unstructured":"Hermel, M. et al. Highlights of cardiovascular disease prevention studies presented at the 2023 American Heart Association Scientific Sessions. Curr. Atheroscler. Rep. 26, 119\u2013131 (2024).","journal-title":"Curr. Atheroscler. Rep."},{"key":"4254_CR29","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1093\/eurheartj\/ehaf411","volume":"46","author":"C Gurevitz","year":"2025","unstructured":"Gurevitz, C. et al. Gene therapy and genome editing for lipoprotein disorders. Eur. Heart J. 46, 3420\u20133433 (2025).","journal-title":"Eur. Heart J."},{"key":"4254_CR30","doi-asserted-by":"publisher","first-page":"A4139206","DOI":"10.1161\/circ.150.suppl_1.4139206","volume":"150","author":"S Vafai","year":"2024","unstructured":"Vafai, S. et al. Abstract 4139206: Design of Heart-2: a phase 1b clinical trial of VERVE-102, an in vivo base editing medicine delivered by a GalNAc-LNP and targeting PCSK9 to durably lower LDL cholesterol. Circulation 150, A4139206 (2024).","journal-title":"Circulation"},{"key":"4254_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"4254_CR32","doi-asserted-by":"crossref","unstructured":"Feng, Y. et al. Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation. Nat. Mater. 24, 1826\u20131839 (2025).","DOI":"10.1038\/s41563-025-02284-w"},{"key":"4254_CR33","doi-asserted-by":"publisher","first-page":"27977","DOI":"10.1021\/acsnano.5c10648","volume":"19","author":"Y Kawaguchi","year":"2025","unstructured":"Kawaguchi, Y. et al. Modulating immunogenicity and reactogenicity in mRNA-lipid nanoparticle vaccines through lipid component optimization. ACS Nano 19, 27977\u201328001 (2025).","journal-title":"ACS Nano"},{"key":"4254_CR34","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.omtn.2021.03.008","volume":"24","author":"N Davies","year":"2021","unstructured":"Davies, N. et al. Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein. Mol. Ther. Nucleic Acids 24, 369\u2013384 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"4254_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder, M. L. et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat. Med. 25, 229\u2013233 (2019).","journal-title":"Nat. Med."},{"key":"4254_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-022-00636-2","volume":"19","author":"M Chavez","year":"2023","unstructured":"Chavez, M., Chen, X., Finn, P. B. & Qi, L. S. Advances in CRISPR therapeutics. Nat. Rev. Nephrol. 19, 9\u201322 (2023).","journal-title":"Nat. Rev. Nephrol."},{"key":"4254_CR37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357\u20131364 (2010).","journal-title":"Mol. Ther."},{"key":"4254_CR38","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair, J. K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958\u201316961 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"4254_CR39","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/cpt.3213","volume":"115","author":"JJ Li","year":"2024","unstructured":"Li, J. J. et al. Chinese expert consensus on the clinical diagnosis and management of statin intolerance. Clin. Pharmacol. Ther. 115, 954\u2013964 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4254_CR40","doi-asserted-by":"crossref","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","DOI":"10.1016\/j.celrep.2018.02.014"}],"updated-by":[{"DOI":"10.1038\/s41591-026-04786-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:00:00Z","timestamp":1793664000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04254-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:08:11Z","timestamp":1793833691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4254"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04254-4","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04786-9","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04786-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.X., X.M., Y. Liu and W.Y. are employees of YolTech Therapeutics. M.O is a member of the advisory board for YolTech Therapeutics. Y. Lu, Z.J.W. and Y.W. are cofounders of YolTech Therapeutics. YOLT-101, the investigational product used in this study, is developed by YolTech Therapeutics. These relationships did not influence the study design, data collection, analysis or interpretation. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}